<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01960907</url>
  </required_header>
  <id_info>
    <org_study_id>CHROMEDB</org_study_id>
    <nct_id>NCT01960907</nct_id>
  </id_info>
  <brief_title>Clinical Trials for Elderly Patients With Multiple Disease</brief_title>
  <acronym>CHROMED</acronym>
  <official_title>Clinical Trials for Elderly Patients With Multiple Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Restech Srl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Liverpool</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Lincoln</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Tallin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Barcelona</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital of Sezana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of North Norway</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tesan spa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Restech Srl</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The CHROMED project focuses its investigation on the applicability of an integrated solution
      for a pathological condition which: a) is very prevalent in ageing patients and b) severely
      impairs quality of life: COPD with other typical comorbidities such as congestive heart
      failure and sleep disordered breathing. A specific ICT platform in combination with a set of
      innovative devices will be used to collect and process useful clinical data at the patient's
      home and used to optimize their medical treatment. To evaluate the impact of this solution,
      an international multi-centric randomized control trial will be implemented in five European
      regions: United Kingdom, Sweden, Estonia, Spain and Slovenia, representing different social
      and organizational contexts in Europe.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to First Hospitalization</measure>
    <time_frame>From enrolment up to 9 months</time_frame>
    <description>It represents the number of days, since the enrolment into the study, to the first hospitalization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Final Utility Index of EQ-5D Questionnaire</measure>
    <time_frame>9 months</time_frame>
    <description>The quality of life of patients as quantified by the final utility index of the EQ-5D questionnaire. The utility index ranges from -0.074 to 1 with 1 being the highest possible quality of life.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">312</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <condition>Congestive Heart Failure (CHF)</condition>
  <condition>Sleep Disordered Breathing (SDB)</condition>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in the observational arm will receive monthly interviews for collecting informations about their status and level of utilization of healthcare resources.
They will follow their usual care path as provided by their local NHS</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Interventional</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a system form monitoring their health status.
The system is composed by:
a touch-screen pc for the administration of daily questionnaires
RESMONPRO DIARY for the measurement of lung mechanical impedance and breathing pattern
a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.
Subjects will receive medical treatment following the activation of alarms by the monitoring devices.
Monthly phone interviews will be performed to collect data about their level of utilization of the health care system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CHROMED monitoring system</intervention_name>
    <description>Optimization of patient's treatment according to the data collected by the home monitoring devices</description>
    <arm_group_label>Interventional</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  COPD GOLD grade II or higher with a prior history of exacerbations and/or an
             hospitalization for COPD in the previous year with one or more documented
             non-pulmonary chronic conditions such as:

          -  CHF due to left ventricular systolic dysfunction (LVSD) confirmed on echocardiography

          -  SDB identified by respiratory sleeping studies or polysomnography

          -  current or prior smoking history of &gt;= 10 pack/years

          -  subjects capable of providing signed written informed consent

          -  subjects capable of perform study procedures and use the RESMONPRO at home

          -  subjects with reliable mobile phone coverage at home

        Exclusion Criteria:

          -  Any disease that, in the opinion of the investigator, put the subject at risk

          -  subjects with significant vision disturbance and mental diseases

          -  subjects with a planned prolonged absence from home
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter Calverley, Phd, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Liverpool</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Clinical Medicine</name>
      <address>
        <city>Tallin</city>
        <zip>12618</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bolnisnica Sežana Zavod</name>
      <address>
        <city>Sežana</city>
        <zip>6210</zip>
        <country>Slovenia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lincolnshire Community Health Service</name>
      <address>
        <city>Lincoln</city>
        <zip>LN6 7TS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aintree University Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Slovenia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.chromed.eu/</url>
    <description>Official website of the CHROMED project</description>
  </link>
  <reference>
    <citation>Brouwer AF, Visser CA, Duiverman EJ, Roorda RJ, Brand PL. Is home spirometry useful in diagnosing asthma in children with nonspecific respiratory symptoms? Pediatr Pulmonol. 2010 Apr;45(4):326-32. doi: 10.1002/ppul.21183.</citation>
    <PMID>20196110</PMID>
  </reference>
  <reference>
    <citation>Dellacà RL, Santus P, Aliverti A, Stevenson N, Centanni S, Macklem PT, Pedotti A, Calverley PM. Detection of expiratory flow limitation in COPD using the forced oscillation technique. Eur Respir J. 2004 Feb;23(2):232-40.</citation>
    <PMID>14979497</PMID>
  </reference>
  <reference>
    <citation>Dellacà RL, Pompilio PP, Walker PP, Duffy N, Pedotti A, Calverley PM. Effect of bronchodilation on expiratory flow limitation and resting lung mechanics in COPD. Eur Respir J. 2009 Jun;33(6):1329-37. doi: 10.1183/09031936.00139608. Epub 2009 Jan 22.</citation>
    <PMID>19164347</PMID>
  </reference>
  <reference>
    <citation>Dellacà R, Montserrat JM, Govoni L, Pedotti A, Navajas D, Farré R. Telemetric CPAP titration at home in patients with sleep apnea-hypopnea syndrome. Sleep Med. 2011 Feb;12(2):153-7. doi: 10.1016/j.sleep.2010.07.014. Epub 2011 Jan 17.</citation>
    <PMID>21247800</PMID>
  </reference>
  <reference>
    <citation>Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2004 Jun 15;169(12):1298-303. Epub 2004 Feb 27.</citation>
    <PMID>14990395</PMID>
  </reference>
  <reference>
    <citation>McKinstry B, Pinnock H, Sheikh A. Telemedicine for management of patients with COPD? Lancet. 2009 Aug 29;374(9691):672-3. doi: 10.1016/S0140-6736(09)61542-7. Review.</citation>
    <PMID>19716948</PMID>
  </reference>
  <reference>
    <citation>Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax. 2010 Nov;65(11):956-62. doi: 10.1136/thx.2009.128082. Epub 2010 Sep 25.</citation>
    <PMID>20871122</PMID>
  </reference>
  <reference>
    <citation>Vinson JM, Rich MW, Sperry JC, Shah AS, McNamara T. Early readmission of elderly patients with congestive heart failure. J Am Geriatr Soc. 1990 Dec;38(12):1290-5.</citation>
    <PMID>2254567</PMID>
  </reference>
  <reference>
    <citation>MacDonald M, Fang J, Pittman SD, White DP, Malhotra A. The current prevalence of sleep disordered breathing in congestive heart failure patients treated with beta-blockers. J Clin Sleep Med. 2008 Feb 15;4(1):38-42.</citation>
    <PMID>18350960</PMID>
  </reference>
  <reference>
    <citation>Polisena J, Tran K, Cimon K, Hutton B, McGill S, Palmer K, Scott RE. Home telehealth for chronic obstructive pulmonary disease: a systematic review and meta-analysis. J Telemed Telecare. 2010;16(3):120-7. doi: 10.1258/jtt.2009.090812. Epub 2010 Mar 2. Review.</citation>
    <PMID>20197355</PMID>
  </reference>
  <reference>
    <citation>Rutten FH, Cramer MJ, Lammers JW, Grobbee DE, Hoes AW. Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail. 2006 Nov;8(7):706-11. Epub 2006 Mar 13. Review.</citation>
    <PMID>16531114</PMID>
  </reference>
  <reference>
    <citation>Calverley P, Pauwels Dagger R, Löfdahl CG, Svensson K, Higenbottam T, Carlsson LG, Ståhl E. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur Respir J. 2005 Sep;26(3):406-13. Erratum in: Eur Respir J. 2006 Feb;27(2):440.</citation>
    <PMID>16135720</PMID>
  </reference>
  <reference>
    <citation>Spencer S, Calverley PM, Burge PS, Jones PW. Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J. 2004 May;23(5):698-702.</citation>
    <PMID>15176682</PMID>
  </reference>
  <reference>
    <citation>McNicholas WT. Chronic obstructive pulmonary disease and obstructive sleep apnea: overlaps in pathophysiology, systemic inflammation, and cardiovascular disease. Am J Respir Crit Care Med. 2009 Oct 15;180(8):692-700. doi: 10.1164/rccm.200903-0347PP. Epub 2009 Jul 23.</citation>
    <PMID>19628778</PMID>
  </reference>
  <reference>
    <citation>Johnson MK, Birch M, Carter R, Kinsella J, Stevenson RD. Measurement of physiological recovery from exacerbation of chronic obstructive pulmonary disease using within-breath forced oscillometry. Thorax. 2007 Apr;62(4):299-306. Epub 2006 Nov 14.</citation>
    <PMID>17105778</PMID>
  </reference>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2013</study_first_submitted>
  <study_first_submitted_qc>October 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 11, 2013</study_first_posted>
  <results_first_submitted>July 26, 2016</results_first_submitted>
  <results_first_submitted_qc>September 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">September 30, 2016</results_first_posted>
  <last_update_submitted>September 29, 2016</last_update_submitted>
  <last_update_submitted_qc>September 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Restech Srl</investigator_affiliation>
    <investigator_full_name>Pasquale Pio Pompilio</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>CHF</keyword>
  <keyword>SDB</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Observational</title>
          <description>Subjects in the observational arm received monthly interviews for collecting informations about their status and level of utilization of healthcare resources.
They followed their usual care path as provided by their local NHS.</description>
        </group>
        <group group_id="P2">
          <title>Interventional</title>
          <description>Patients received a system for monitoring their health status.
The system is composed by:
a touch-screen pc for the administration of daily questionnaires
RESMON PRO DIARY for the measurement of lung mechanical impedance and breathing pattern
a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.
Subjects received medical treatment following the activation of alarms by the monitoring devices.
Monthly phone interviews were performed to collect data bout their status and level of utilization of healthcare resources.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="158"/>
                <participants group_id="P2" count="154"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="109"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="36"/>
                <participants group_id="P2" count="45"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="42"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Observational</title>
          <description>Subjects in the observational arm received monthly interviews for collecting informations about their status and level of utilization of healthcare resources.
They followed their usual care path as provided by their local NHS</description>
        </group>
        <group group_id="B2">
          <title>Interventional</title>
          <description>Patients received a system for monitoring their health status.
The system is composed by:
a touch-screen pc for the administration of daily questionnaires
RESMON PRO DIARY for the measurement of lung mechanical impedance and breathing pattern
a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.
Subjects received additional medical treatment following the activation of alarms by the monitoring devices.
Monthly phone interviews were performed to collect data bout their status and level of utilization of healthcare resources.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="158"/>
            <count group_id="B2" value="154"/>
            <count group_id="B3" value="312"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71" lower_limit="65.3" upper_limit="76"/>
                    <measurement group_id="B2" value="71" lower_limit="66" upper_limit="75.8"/>
                    <measurement group_id="B3" value="71" lower_limit="66" upper_limit="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="53"/>
                    <measurement group_id="B3" value="106"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="105"/>
                    <measurement group_id="B2" value="101"/>
                    <measurement group_id="B3" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Sweden</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Slovenia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Estonia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 postBD</title>
          <description>Spirometrically measured Forced Exhaled Volume in 1 second (FEV1), measured after a maximal dose of a bronchodilator drug</description>
          <units>L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.3" lower_limit="0.9" upper_limit="1.8"/>
                    <measurement group_id="B2" value="1.3" lower_limit="1.0" upper_limit="1.6"/>
                    <measurement group_id="B3" value="1.3" lower_limit="1.0" upper_limit="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1 postBD %pred</title>
          <description>Forced Exhaled Volume in 1 second (FEV1) measured after the administration of a maximal dose of bronchodilator expressed as percentage of predicted value.</description>
          <units>%predicted</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.4" lower_limit="38" upper_limit="63.9"/>
                    <measurement group_id="B2" value="49.4" lower_limit="37.1" upper_limit="59.2"/>
                    <measurement group_id="B3" value="49.8" lower_limit="37.2" upper_limit="62.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FVC postBD</title>
          <description>Forced Vital Capacity (FVC) after brochodilation: maximum volume of air exhaled during a full forced exhalation from the maximum to the minimum lung volume achievable by the subject measured after the administration of a maximal dose of a bronchodilator drug.</description>
          <units>L</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" lower_limit="2.1" upper_limit="3.1"/>
                    <measurement group_id="B2" value="2.6" lower_limit="2.0" upper_limit="3.1"/>
                    <measurement group_id="B3" value="2.5" lower_limit="2.0" upper_limit="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FVC postBD %pred</title>
          <description>Forced Vital Capacity measured after bronchodilation expressed as percentage of its predicted value.</description>
          <units>%predicted</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="75.8" lower_limit="63.0" upper_limit="89.7"/>
                    <measurement group_id="B2" value="73.8" lower_limit="61.8" upper_limit="88.0"/>
                    <measurement group_id="B3" value="75.0" lower_limit="62.2" upper_limit="89.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>FEV1/FVC postBD</title>
          <description>Ratio between Forced Exhaled Volume in 1 second (FEV1) and the Forced Vital capacity (FVC)</description>
          <units>ratio</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.5" lower_limit="0.4" upper_limit="0.6"/>
                    <measurement group_id="B2" value="0.5" lower_limit="0.4" upper_limit="0.6"/>
                    <measurement group_id="B3" value="0.5" lower_limit="0.4" upper_limit="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with two or more COPD exacerbation in the previous year</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="99"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Patients with one or more hospitalization in the previous year</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Time to First Hospitalization</title>
        <description>It represents the number of days, since the enrolment into the study, to the first hospitalization</description>
        <time_frame>From enrolment up to 9 months</time_frame>
        <population>An intention to treat analysis has been applied for the primary outcomes of the trial and all the randomized patients have been retained for the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Observational</title>
            <description>Subjects in the observational arm received monthly interviews for collecting informations about their status and level of utilization of healthcare resources.
They followed their usual care path as provided by their local NHS</description>
          </group>
          <group group_id="O2">
            <title>Interventional</title>
            <description>Patients received a system for monitoring their health status.
The system is composed by:
a touch-screen pc for the administration of daily questionnaires
RESMON PRO DIARY for the measurement of lung mechanical impedance and breathing pattern
a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.
Subjects received additional medical treatment following the activation of alarms by the monitoring devices.
Monthly phone interviews were performed to collect data bout their status and level of utilization of healthcare resources.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Hospitalization</title>
          <description>It represents the number of days, since the enrolment into the study, to the first hospitalization</description>
          <population>An intention to treat analysis has been applied for the primary outcomes of the trial and all the randomized patients have been retained for the analysis.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255" lower_limit="240" upper_limit="270"/>
                    <measurement group_id="O2" value="224" lower_limit="209" upper_limit="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.342</p_value>
            <method>Log Rank</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Final Utility Index of EQ-5D Questionnaire</title>
        <description>The quality of life of patients as quantified by the final utility index of the EQ-5D questionnaire. The utility index ranges from -0.074 to 1 with 1 being the highest possible quality of life.</description>
        <time_frame>9 months</time_frame>
        <population>An intention to treat analysis has been applied for the primary outcomes of the trial. Multiple Imputation (MI) was used to assign values were data were missing. However for a limited number of patient, due to the fact that all data were missing, we couldn't apply any imputation method and therefore they have been excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Observational</title>
            <description>Subjects in the observational arm received monthly interviews for collecting informations about their status and level of utilization of healthcare resources.
They followed their usual care path as provided by their local NHS.</description>
          </group>
          <group group_id="O2">
            <title>Interventional</title>
            <description>Patients received a system for monitoring their health status.
The system is composed by:
a touch-screen pc for the administration of daily questionnaires
RESMON PRO DIARY for the measurement of lung mechanical impedance and breathing pattern
a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.
Subjects received additional medical treatment following the activation of alarms by the monitoring devices.
Monthly phone interviews were performed to collect data bout their status and level of utilization of healthcare resources.</description>
          </group>
        </group_list>
        <measure>
          <title>Final Utility Index of EQ-5D Questionnaire</title>
          <description>The quality of life of patients as quantified by the final utility index of the EQ-5D questionnaire. The utility index ranges from -0.074 to 1 with 1 being the highest possible quality of life.</description>
          <population>An intention to treat analysis has been applied for the primary outcomes of the trial. Multiple Imputation (MI) was used to assign values were data were missing. However for a limited number of patient, due to the fact that all data were missing, we couldn't apply any imputation method and therefore they have been excluded.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="153"/>
                <count group_id="O2" value="150"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.640" spread="0.248"/>
                    <measurement group_id="O2" value="0.637" spread="0.225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.915</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Difference of Hospitalization Rate</title>
        <description>Difference between the hospitalization rate during the study and the previous year. For each patient, hospitalization rate was defined as the number of hospital admissions during a period divided by the length (in days) of the period. Number of hospitalizations was collected by the hospital clinical records.</description>
        <time_frame>Baseline and 9 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Monitored, Previously Hopitalized for COPD Exacerbation</title>
            <description>Patients in the monitored group that were hospitalized the year before the study for a COPD exacerbation</description>
          </group>
          <group group_id="O2">
            <title>Observational, Previously Hopitalized for COPD Exacerb.</title>
            <description>Patients in the observational group that were hospitalized the year before the study for a COPD exacerbation</description>
          </group>
        </group_list>
        <measure>
          <title>Difference of Hospitalization Rate</title>
          <description>Difference between the hospitalization rate during the study and the previous year. For each patient, hospitalization rate was defined as the number of hospital admissions during a period divided by the length (in days) of the period. Number of hospitalizations was collected by the hospital clinical records.</description>
          <units>hospitalizations/year/patient</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1" lower_limit="-1" upper_limit="-0.15"/>
                    <measurement group_id="O2" value="-1" lower_limit="-1" upper_limit="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Observational</title>
          <description>Subjects in the observational arm received monthly interviews for collecting informations about their status and level of utilization of healthcare resources.
They followed their usual care path as provided by their local NHS</description>
        </group>
        <group group_id="E2">
          <title>Interventional</title>
          <description>Patients received a system for monitoring their health status.
The system is composed by:
a touch-screen pc for the administration of daily questionnaires
RESMON PRO DIARY for the measurement of lung mechanical impedance and breathing pattern
a Medic4all Wrist Clinic for the assessment of heart rate, blood pressure, saturation, 1 lead ECG, body temperature.
Subjects received additional medical treatment following the activation of alarms by the monitoring devices.
Monthly phone interviews were performed to collect data bout their status and level of utilization of healthcare resources.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="158"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="154"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Pasquale Pio Pompilio, R&amp;D manager</name_or_title>
      <organization>RESTECH srl</organization>
      <phone>+39 02 3659 3690</phone>
      <email>p.pompilio@restech.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

